Revelier

Revelier was built with a clear vision: transform how healthcare data flows between payers (insurance companies) and providers (doctors and health systems). The founder recognized that healthcare's traditional fee-for-service model created misaligned incentives—doctors weren't rewarded for keeping patients healthy long-term. Value-based care promised to fix this, but the market was still being served by armies of offshore workers manually digesting clinical data. The founder saw an opportunity to automate this with AI and workflow tools.

The journey wasn't a straight line. It took six years to grow from $1M to $25M ARR—a grinding climb punctuated by moments of doubt. The 2019 introduction of machine learning to read medical records was a turning point: the platform began ingesting nearly 1 billion pages of medical records annually (roughly 3,000 pages per minute). Then COVID-19 hit. Despite being in government-sponsored healthcare, the market shut down. But by 2021, momentum returned. That year marked a watershed moment: Oak HC FT invested, bringing not just capital but a transformational partnership vision. By November 2021, they closed their institutional funding round.

The early days involved grit—literal grit. The founder mortgaged his house in 2018 to bridge a payroll crisis, betting everything on the vision and team. Early wins came through partnerships before acquisitions became the growth engine. A lighthouse customer in the payer space became a national health plan, validating the product. The average deal size grew from under $200k in 2021 to over $800k by 2024, reflecting deeper enterprise penetration and expanded solutions.

The real acceleration came through strategic, product-driven M&A. Between 2022 and 2023, Revelier acquired two companies that rounded out their solution set and moved them from serving payers into the provider space—expanding the TAM by $6.5B in the process. Roughly 10% of their $100M current revenue comes from acquired revenue, but the acquisitions drove much greater product expansion. The deal structure evolved too: the first was 75% cash/25% equity, the second became 50/50, and the third acquisition is being funded entirely by debt—proof of their strong cash generation. However, customer success stumbled: a demanding lighthouse customer was treated as a problem rather than a priority, leading to a non-renewal notice that threatened 30% layoffs. The crisis forced a rapid recovery: they signed a customer four times larger within 60 days and rebuilt their customer success function.

Revelier is scaling aggressively toward billion-dollar status. With $100M in revenue this year and $105-110M projected ARR, they're on track for $200M next year. The go-to-market team expanded from 2 reps in 2021 to a specialized, multi-segment sales force. R&D and AI engineering headcount have surged. The TAM has grown from $2B to $20B with a clear path to a $500M+ business. They've raised $65M in debt from Hercules Capital alongside institutional equity partners (Oak HC FT, Upfront Ventures), giving them flexibility to fund acquisitions without excessive dilution. The founder's learnings are clear: talent must be constantly upgraded as the company scales; in vertical SaaS, scale through M&A is not optional; and customer success is non-negotiable when you have lumpy, enterprise deals. The superpower remains data ingestion and AI—distilling massive clinical datasets into actionable 3-5 recommendations for doctors during patient visits.